E-2-(4-isobutylphenyl) ethenesulfonic acid sodium salt | 756501-47-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: E-2-(4-isobutylphenyl) ethenesulfonic acid sodium salt
• 英文别名: sodium;(E)-2-[4-(2-methylpropyl)phenyl]ethenesulfonate
• CAS: 756501-47-0
• 化学式: C₁₂H₁₅O₃S*Na
• 分子量: 262.305
• InChiKey: LIDBRFYLEADHMF-USRGLUTNSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.59
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Sulfonic acids, their derivatives and pharmaceutical compositions containing them
  申请人：Dompé S.P.A.

  公开号：EP1457485A1

  公开（公告）日：2004-09-15

  Selected sulfonic acids, their derivatives and pharmaceutical compositions containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, the selected sulfonic acids and their derivativas are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.

  选择性磺酸、它们的衍生物和含有这些化合物的药物组合物在抑制由白细胞介素-8（IL-8）与CXCR1和CXCR2膜受体相互作用引起的中性粒细胞（PMN白细胞）趋化活化方面是有用的。这些化合物用于预防和治疗由该活化引起的病理状况。值得注意的是，所选的磺酸及其衍生物不具有环氧化酶抑制活性，特别适用于治疗中性粒细胞依赖性病理状况，如银屑病、溃疡性结肠炎、黑色素瘤、慢性阻塞性肺疾病（COPD）、大疱性类天疱疮、类风湿性关节炎、特发性纤维化、肾小球肾炎以及预防和治疗缺血再灌注引起的损伤。
• SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Dompé S.P.A.

  公开号：EP1606248A2

  公开（公告）日：2005-12-21
• US7737139B2
  申请人：——

  公开号：US7737139B2

  公开（公告）日：2010-06-15
• [EN] SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] ACIDES SULFONIQUES, LEURS DERIVES ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES
  申请人：DOMPE SPA

  公开号：WO2004080951A2

  公开（公告）日：2004-09-23

  Selected sulfonic acids, their derivatives and pharmaceutical compositions containing such compounds are useful in inhibiting the chernotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCRI and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, the selected sulfonic acids and their derivativas are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.